Stock NEWBRY NEWBURY PHARMACEUTICALS AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Newbury Pharmaceuticals AB

Equities

NEWBRY

SE0015244884

Market Closed - Nasdaq Stockholm
Other stock markets
 11:17:46 2024-06-20 EDT 		5-day change 1st Jan Change
3.46 SEK +8.81% Intraday chart for Newbury Pharmaceuticals AB +8.12% +12.70%
04-10 Newbury Pharmaceuticals AB Reports Earnings Results for the Second Quarter and Six Months Ended February 29, 2024 CI
02-22 Newbury Pharmaceuticals Secures SEK9 Million Sales Order MT

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
NEWBURY PHARMACEUTICALS AB Stock Newbury Pharmaceuticals AB
+12.70% 7.4M - -
RAIA DROGASIL S.A. Stock Raia Drogasil S.A.
-16.43% 7.78B
B
AIN HOLDINGS INC. Stock Ain Holdings Inc.
+30.84% 1.32B -
QOL HOLDINGS CO., LTD. Stock Qol Holdings Co., Ltd.
-12.79% 343M -
NIHON CHOUZAI CO.,LTD. Stock NIHON CHOUZAI Co.,Ltd.
+2.79% 275M -
SALUS, LJUBLJANA, D. D. Stock SALUS, Ljubljana, d. d.
+8.89% 222M - -
GREEN CROSS HEALTH LIMITED Stock Green Cross Health Limited
-25.69% 73.97M - -
MEDICAL IKKOU GROUP CO.,LTD. Stock Medical Ikkou Group Co.,Ltd.
+28.21% 61.04M - -
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
-
4 months EPS revision
-

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. NEWBRY Stock
  4. Ratings Newbury Pharmaceuticals AB